Where did he say that? I didn't see AMBS mentioned is his tweet?

Here's what Jason has been saying this month on Amarantus:

Quote:

---

Our take on the story is that there is simply too much going on at Amarantus to keep the stock under ten cents for much longer.

---

Quote:

---

Speaking of credibility, the recent news that the U.S. FDA granted MANF an Orphan Drug designation for Retinitis Pigmentosa (RP) in late December 2014 was a huge win for Amarantus.

---

Quote:

---

Amarantus is now loaded with catalysts.

---